JP2020502125A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502125A5
JP2020502125A5 JP2019531759A JP2019531759A JP2020502125A5 JP 2020502125 A5 JP2020502125 A5 JP 2020502125A5 JP 2019531759 A JP2019531759 A JP 2019531759A JP 2019531759 A JP2019531759 A JP 2019531759A JP 2020502125 A5 JP2020502125 A5 JP 2020502125A5
Authority
JP
Japan
Prior art keywords
ingestible device
ingestible
cecum
integrin inhibitor
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531759A
Other languages
English (en)
Japanese (ja)
Other versions
JP7150723B2 (ja
JP2020502125A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066441 external-priority patent/WO2018112215A1/en
Publication of JP2020502125A publication Critical patent/JP2020502125A/ja
Publication of JP2020502125A5 publication Critical patent/JP2020502125A5/ja
Application granted granted Critical
Publication of JP7150723B2 publication Critical patent/JP7150723B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531759A 2016-12-14 2017-12-14 消化管疾病のインテグリン阻害薬による治療 Active JP7150723B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662434369P 2016-12-14 2016-12-14
US62/434,369 2016-12-14
US201762478863P 2017-03-30 2017-03-30
US62/478,863 2017-03-30
US201762545220P 2017-08-14 2017-08-14
US62/545,220 2017-08-14
US201762583804P 2017-11-09 2017-11-09
US62/583,804 2017-11-09
PCT/US2017/066441 WO2018112215A1 (en) 2016-12-14 2017-12-14 Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Publications (3)

Publication Number Publication Date
JP2020502125A JP2020502125A (ja) 2020-01-23
JP2020502125A5 true JP2020502125A5 (enExample) 2021-01-28
JP7150723B2 JP7150723B2 (ja) 2022-10-11

Family

ID=60953955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531759A Active JP7150723B2 (ja) 2016-12-14 2017-12-14 消化管疾病のインテグリン阻害薬による治療

Country Status (11)

Country Link
US (1) US20200253506A1 (enExample)
EP (2) EP3554539B9 (enExample)
JP (1) JP7150723B2 (enExample)
KR (1) KR20190095936A (enExample)
CN (2) CN110167589B (enExample)
AU (1) AU2017376801B9 (enExample)
BR (1) BR112019012071A2 (enExample)
CA (1) CA3045931A1 (enExample)
MX (1) MX2019006867A (enExample)
TW (1) TW201834710A (enExample)
WO (1) WO2018112215A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220135666A1 (en) * 2017-12-14 2022-05-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a s1p modulator
US20200390426A1 (en) * 2017-12-22 2020-12-17 Aobiome Llc Devices and methods for microbiome sampling
WO2019246455A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN112804928A (zh) * 2018-10-03 2021-05-14 奥林巴斯株式会社 内窥镜装置以及观察时间测量方法
US20230096620A1 (en) * 2019-04-17 2023-03-30 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
EP3870261B1 (en) * 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2020405301B2 (en) * 2019-12-16 2024-02-29 Eli Lilly And Company Capsule for gastrointestinal sampling
WO2022185323A1 (en) * 2021-03-05 2022-09-09 Photopill Medical Ltd Device and method for gastrointestinal location estimation
EP4314766A4 (en) * 2021-04-01 2025-05-07 Medibeacon Inc. METHODS FOR MONITORING MUCOSA HEALING
JP7699774B2 (ja) * 2021-09-07 2025-06-30 公立大学法人名古屋市立大学 間質性膀胱炎・膀胱痛症候群の予防又は治療用医薬組成物
CN114659995B (zh) * 2022-05-24 2022-08-23 广东省农业科学院动物科学研究所 一种基于显微高光谱的鱼类诱食剂效果评价方法及系统
CN114907468B (zh) * 2022-06-10 2023-05-23 东莞理工学院 一种仿刺参整合素多克隆抗体、抗原蛋白及其制备方法
CN116027048A (zh) * 2023-02-06 2023-04-28 山东中鸿特检生物科技有限公司 一种细胞因子风暴综合征诊断试剂盒及其应用
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2025050006A1 (en) * 2023-09-01 2025-03-06 Biora Therapeutics, Inc. Ingestible drug delivery device

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4190328A (en) 1978-12-01 1980-02-26 Levine Robert A Process for detection of blood-borne parasites
DE2928477C3 (de) * 1979-07-14 1982-04-15 Battelle-Institut E.V., 6000 Frankfurt Vorrichtung zur Freisetzung von Substanzen an definierten Orten des Verdauungstraktes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5314805A (en) 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
US5596090A (en) 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT1007033E (pt) 1997-08-28 2008-07-22 Novartis Ag Antagonistas do antigénio-1 da função de linfócitos
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999042838A1 (en) 1998-02-18 1999-08-26 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EA006301B1 (ru) 1999-01-22 2005-10-27 Элан Фармасьютикалз, Инк. Ацильные производные, используемые для лечения опосредованных vla-4 расстройств
US8636648B2 (en) * 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US6331530B1 (en) 1999-07-13 2001-12-18 The Trustees Of Columbia University In The City Of New York Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen
US6703248B1 (en) 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
KR100767000B1 (ko) 2000-02-03 2007-10-15 에자이 알앤드디 매니지먼트 가부시키가이샤 인테그린 발현 저해제
NZ521437A (en) 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
AU2001262089A1 (en) 2000-03-14 2001-09-24 Novartis Ag Alpha4beta1 and alpha4beta7 integrin inhibitors
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
JP2004521680A (ja) * 2001-01-22 2004-07-22 ヴイ−ターゲット テクノロジーズ リミテッド 摂取可能な装置
US7160258B2 (en) * 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
US6949347B2 (en) 2002-03-05 2005-09-27 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
EP2336185A1 (en) 2002-03-13 2011-06-22 Biogen Idec Inc. Anti- alpha v beta 6 antibodies
CN1665490A (zh) * 2002-07-05 2005-09-07 特姆雷尔公司 控释组合物
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
JP2006517827A (ja) * 2003-01-29 2006-08-03 イー−ピル・ファーマ・リミテッド 胃腸管内における活性薬物の送達
DE10305784A1 (de) 2003-02-12 2004-08-26 Merck Patent Gmbh Verfahren zur Herstellug bicyclischer aromatischer Aminosäuren sowie deren Zwischenprodukte
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20070059316A1 (en) 2003-09-23 2007-03-15 Pallenberg Alexander J Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents
ATE399542T1 (de) 2003-10-01 2008-07-15 Merck Patent Gmbh Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
WO2005035495A2 (en) 2003-10-08 2005-04-21 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
MY145329A (en) * 2004-03-26 2012-01-31 Lek Pharmaceuticals Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
WO2006023420A2 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
DK176145B1 (da) 2004-09-23 2006-10-02 Guldmann V As Kobling
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102004059613A1 (de) * 2004-12-10 2006-06-14 Liedtke, Rainer K., Dr. Zusammensetzung und Methode einer topischen Therapie von Neurodermitis
JP2008532568A (ja) * 2005-01-18 2008-08-21 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 電子制御されるカプセル
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
WO2007054128A1 (en) 2005-11-14 2007-05-18 Dominion Pharmakine S.L. Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
CA2608073C (en) 2005-05-20 2013-08-06 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520378D0 (en) 2005-10-06 2005-11-16 Novartis Ag Organic compounds
WO2007059195A1 (en) 2005-11-14 2007-05-24 University Of Southern California Integrin-binding small molecules
EP1961750B1 (en) 2005-12-13 2013-09-18 Daiichi Sankyo Company, Limited Vla-4 inhibitory drug
CA2643838A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
KR101454491B1 (ko) 2006-03-21 2014-10-29 제넨테크, 인크. 알파5베타1 길항제를 포함하는 조합 치료법
JP2009536641A (ja) 2006-05-31 2009-10-15 ハンワ ケミカル コーポレイション Vcam−1特異的モノクローナル抗体
CN101472640B (zh) * 2006-06-23 2012-12-12 皇家飞利浦电子股份有限公司 药物输送系统
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
US20100145301A1 (en) * 2007-02-26 2010-06-10 Duocure, Inc. Spray administration of compositions including active agents such as peptides to the gastrointestinal tract
CN101990429A (zh) * 2007-04-04 2011-03-23 希格默伊德药业有限公司 一种口服药物组合物
US8562986B2 (en) 2007-07-17 2013-10-22 Merck Patent Gmbh Engineered anti-alpha V-integrin hybrid antibodies
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
WO2011004395A1 (en) 2009-07-06 2011-01-13 Intas Biopharmaceuticals Limited Microemulsion formulation for biologicals
US20120136209A1 (en) * 2009-08-05 2012-05-31 Tel Hashomer Medical Research Infrastructure And Services, Ltd. Methods and devices for providing information useful in the diagnosis of abnormalities of the gastrointestinal tract
KR101277406B1 (ko) 2009-10-23 2013-06-21 한화케미칼 주식회사 Vcam-1에 특이적으로 결합하고 백혈구와 내피세포의 접착 및 투과를 저해하는 재조합 인간 단일클론항체
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
EP2547693B1 (en) 2010-03-19 2015-03-11 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
EP2563405A1 (en) 2010-04-30 2013-03-06 Elan Pharmaceuticals Inc. Selective integrin inhibitors
US9415004B2 (en) * 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
PT2744802T (pt) 2011-08-17 2017-03-15 Piramal Imaging Sa Compostos para ligação às glicoproteínas iib/iiia específicas de plaquetas e a sua utilização em imagiologia de trombos
FR2979346B1 (fr) 2011-08-23 2013-09-27 Univ Joseph Fourier Nanocorps anti-vcam-1
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
FR2986432B1 (fr) 2012-02-06 2014-03-14 Univ Lille Ii Droit & Sante Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17
GB201207155D0 (en) 2012-04-24 2012-06-06 Isis Innovation Antibodies
US20140349944A1 (en) 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
RU2015155590A (ru) 2013-05-24 2017-06-29 Нестек С.А. Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника
US10472376B2 (en) * 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
EP3750590B8 (en) * 2013-09-26 2025-08-13 BT Bidco, Inc. Delivery capsule with threshold release
CN105848557B (zh) * 2013-12-27 2018-09-28 王康怀 具有多光谱光源的胶囊摄影机装置
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
WO2015112575A1 (en) 2014-01-22 2015-07-30 The Board Of Regents Of The University Of Nebraska Gastrointestinal sensor implantation system
ES2818823T3 (es) * 2014-02-27 2021-04-14 Biogen Ma Inc Método de evaluación del riesgo de LMP
DE102014004843A1 (de) 2014-04-02 2015-10-08 Schaltbau Gmbh Gleichstromschütz mit zusätzlicher Schalttauglichkeit für Wechselstromlasten und Polung entgegen der Vorzugsstromrichtung
RU2697851C2 (ru) * 2014-08-13 2019-08-21 Седарс-Синаи Медикал Сентер Антиметаногенные композиции и их применение
SG11201702308TA (en) * 2014-09-25 2017-04-27 Progenity Inc Electromechanical pill device with localization capabilities
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
WO2016099792A1 (en) * 2014-11-19 2016-06-23 Nano Pharmaceutical Laboratories Llc Wireless communications system integrating electronics into orally ingestible products for controlled release of active ingredients
CN104473611B (zh) 2015-01-19 2018-01-30 吉林大学 具有超声波定位功能的胶囊内窥镜系统
KR20170122776A (ko) * 2015-03-06 2017-11-06 신세틱 바이오로직스, 인코퍼레이티드 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
CN118541309A (zh) 2021-11-17 2024-08-23 H2快速帆船有限公司 使用机器人技术制造飞艇的改进系统、方法和设备

Similar Documents

Publication Publication Date Title
JP2020502125A5 (enExample)
JP2020501699A5 (enExample)
JP2020502126A5 (enExample)
JP2020513414A5 (enExample)
JP2020515579A5 (enExample)
AR084610A1 (es) Comprimido de desintegracion oral de lansoprazol
AR041562A1 (es) Preparacion de liberacion controlada
SG10201902347RA (en) Electromechanical pill device with localization capabilities
JP2011088913A5 (enExample)
JP2013514837A5 (enExample)
JP2017532125A5 (enExample)
JP2009502355A5 (enExample)
DK2182839T3 (da) Manchet til bestemmelse af en fysiologisk parameter
AR083422A1 (es) Composiciones y metodos para tratar la hipertension pulmonar
NZ595663A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
CL2015000614A1 (es) Compuesto 2-((4-benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)quinazolin-7-il)oxi)etilo, sus sales o hidratos, inhibidor de rip2 cinasa; compuestos cristalinos; composicion farmaceutica; uso en el tratamiento de enfermedad de crohn, colitis ulcerosa y sindrome de blau.
MX2012014096A (es) Métodos para mejorar el diagnóstico de enfermedad intestinal inflamatoria.
WO2017008026A1 (en) Methods of treating colitis
MX362675B (es) Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina.
JP2011519967A5 (enExample)
AR102228A1 (es) Una formulación de metformina de liberación sostenida y un método de preparación de la misma
CR20150665A (es) Complemento de hierro
NO20092025L (no) Reduksjon av overvekt eller fedme
JP2019059016A5 (enExample)
Podladchikova Modern views on molecular mechanisms of plague pathogenesis